Document is current
Any future updates will be listed below
-
Authors
Liu, Chang
Qin, Henan
Wu, Zeming
Liu, Jiwei
Wang, Minjie
Yao, Jinpeng
Shang, Dong
Yin, Peiyuan
-
Funding
Funding for this research was provided by:
National Natural Science Foundation of China (No. 81873156)
National Key Research and Development Program of China (No. 2018YFE0195200)
key research and development project of Liaoning Province (No.2018225054)
- License Information
-
More Information
Article History
Accepted: 13 July 2025
First Online: 28 January 2026
Declarations
:
: The study was conducted in accordance with the Declaration of Helsinki and approved by the National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College (approval number NCC2021C-348, Nov. 2020), the First Affiliated Hospital of Dalian Medical University (approval number PJ-KS-KY-2021–203, Sep. 2021), and the ethics committee of Changhai Hospital.
: Informed consent was obtained from all subjects involved in the study.
: Z.W. and P.Y. are co-founders of iPhenome (Yun Pu Kang) biotechnology Inc. The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
